| Acceptance rate | 46% |
|---|---|
| Time to first decision | 6 months* |
| Time to decision with review | 50 days* |
*Approximate number of days
**The days mentioned above are averages and do not indicate exact durations. The process may vary for each article.
ACTA Pharmaceutica Sciencia
2021 , Vol 59 , Num 2
Biomarkers in Parkinson's disease - An effective tool for diagnosis of PD
1 Professor and HOD, Dept. of Pharmacology, Sultan-ul-Uloom College of Pharmacy, Road no.3, Banjara Hills Hyderabad - 500034, Telangana, India2 M.Pharm, II-Year, Dept. of Pharmacology, Sultan-ul-Uloom College of Pharmacy, Road no.3, Banjara Hills, Hyderabad - 500034, Telangana, India
3 Principal and Professor, Sultan-ul-Uloom College of Pharmacy, Road no.3, Banjara Hills, Hyderabad - 500034, Telangana, India
DOI : 10.23893/1307-2080.APS.05914 Viewed : 16163 - Downloaded : 5522 Parkinson's disease (PD) ranks the second position of neurodegenerative disorder mainly arises due to depleted levels of neurotransmitter dopamine in substantia nigra. PD is characterized by decreased levels of dopamine due to dopaminergic cell death and manifested by tremor, rigidity, bradykinesia and postural abnormalities. Considerable latency is observed in dopaminergic cell death and appearance of clinical symptoms in PD, so it is necessary to diagnose the disease in early stages for better treatment. Establishment of reliable biomarkers which indicates the progression of the disease and will aid in better clinical management of PD patients. Biomarkers when coupled with system biology tools help in discovering transcriptomic, proteomic, genomic and metabolic molecules and other signaling pathways responsible for differential diagnosis of parkinsonism disorder and serves as tool in monitoring disease progression. Identifying the subjects at earlier stage of disease would pave the way to novel drug therapies to decrease the progression of disease. Keywords : Parkinson"s disease, LRRK2, DJ-1biomarker, neuroimaging biomarkers, reflex tears, ?-synuclein